Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation [PDF]
Frontiers in PharmacologyCoronary microvascular disease (CMVD) has emerged as a new target for the occurrence and development of heart failure treatment. Various indicators such as Index of Microvascular Resistance, Coronary Flow Reserve, Microvascular Resistance Reserve ...
Shaoxin Chen +5 more
doaj +6 more sources
Sodium-glucose co-transporter 2 inhibitors – a review article
Journal of Education, Health and Sport, 2019 Antihyperglycemic interventions have centered on increasing insulin availability, improving insulin sensitivity or restoring β-cell activity to normalize plasma glucose levels in patients with type 2 diabetes mellitus.
Marcin Makuch +3 more
doaj +5 more sources
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Frontiers in Pharmacology, 2022 Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life.
Yuling Jing +3 more
doaj +3 more sources
Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
Perspectives in Clinical Research, 2021 Cardiovascular outcome trials (CVOTs) have to be done by sponsors who wish to launch new antidiabetic drugs in the US, since the December 2008 US Food and Drug Administration ruling, which was subsequently accepted by the European Medicines (Evaluation ...
Viraj Ramesh Suvarna
doaj +4 more sources
Sodium glucose co-transporter 2 inhibitors in heart failure therapy
Türk Kardiyoloji Derneği Arşivi, 2020 Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis.
Yüksel Çavuşoğlu +10 more
doaj +4 more sources
A review of the safety of sodium-glucose co-transporter-2 inhibitors. [PDF]
Diabetes Obes MetabAbstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a
O'Hara DV, Jardine MJ.
europepmc +3 more sources
The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes [PDF]
Nature CommunicationsDiabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu +11 more
doaj +2 more sources
Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension [PDF]
Pulmonary CirculationPatients with borderline pulmonary hypertension (PH) often experience shortness of breath or exacerbation of PH during exercise, known as exercise‐induced PH.
Taijyu Satoh +18 more
doaj +2 more sources
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
Frontiers in Pharmacology, 2022 Daniel H. Van Raalte +1 more
doaj +3 more sources
REPURPOSING SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS FOR GEROTHERAPY [PDF]
Innov AgingAbstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are drugs used to treat T2DM, offering benefits such as reduced HbA1c, weight loss, and improved insulin sensitivity/β-cell function. Additionally, they provide significant cardio-renal benefits, although the exact mechanisms are not fully understood.
Solis-Herrera, Carolina +2 more
europepmc +2 more sources